marzan, I agree that there could be a bidding war for NWBio and its DCVax cancer vaccine platform (L + Direct).
If the DCVax-L Phase III trial turns out to be as successful as we think it will be, and if all future clinical trials for DCVax-L & DCVax Direct for other solid tumor cancer indications, are also successful, then the DCVax platform will be a paradigm shift, and a new standard of care (SOC) for treating solid tumor cancers worldwide.
Even Ken Frazier acknowledged that there could be a possible bidding war for an asset like the DCVax cancer vaccine platform:
“If you're going to try to acquire those assets right now," he added, "you’re going to pay a very steep price, and then a premium on top of it. And on top of that, anytime somebody’s going after something, it turns into a bidding war”
Market Data 
Markets 
AI
